[Viva] Fwd: 19th International AIDS Conference, 22-27 July 2012

Fri Jul 27 14:34:07 PDT 2012

There is a great slide show of the Global Village, plus other info.
Cheers,
Margarite

---------- Forwarded message ----------
From: <aids2012 at nam.org.uk>
Date: Fri, Jul 27, 2012 at 8:05 AM
Subject: 19th International AIDS Conference, 22-27 July 2012
To: margaritesanchez at gmail.com

**

Having trouble reading this email? View it in your browser
<http://www.aidsmap.com/page/2455450?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
           Friday 27th July 2012    Contents

   - How long until a cure? <#138c909e0b08b339_item2455459>
   - One year’s preventive therapy reduces the risk of TB in people on HIV
   treatment <#138c909e0b08b339_item2455463>
   - HIV and TB <#138c909e0b08b339_item2455454>
   - Keeping people in HIV care <#138c909e0b08b339_item2455457>
   - Retaining children in HIV care <#138c909e0b08b339_item2455451>
   - Access to treatment <#138c909e0b08b339_item2455460>
   - HIV and the criminal law <#138c909e0b08b339_item2455456>
   - HIV and hepatitis C <#138c909e0b08b339_item2455452>
   - Hormonal contraception and HIV risk <#138c909e0b08b339_item2455453>
   - The global village <#138c909e0b08b339_item2455458>
   - Support our work <#138c909e0b08b339_item2455455>

 <http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
    How long until a cure?

The panel at the HIV cure press conference. © IAS/Deborah W. Campos -
Commercialimage.net

Some of the latest HIV cure research has been presented at International
AIDS Conference this week.

Experts also met for a cure workshop prior to the
conference<http://www.aidsmap.com/Researchers-step-up-efforts-to-find-an-HIV-cure/page/2445500?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>,
where they launched a global scientific strategy *Towards an HIV Cure.*

Research is looking at a range of different approaches to a possible cure,
including:

   - flushing out and destroying HIV lying dormant in ‘reservoirs’ in the
   body.
   - stem cell treatment (like that which cured the ‘Berlin
Patient<http://www.aidsmap.com/Stem-cell-transplant-has-cured-HIV-infection-in-Berlin-patient-say-doctors/page/1577949?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>’)

   - starting HIV treatment very soon after infection – an approach that
   would only work for a small proportion of people with HIV.

It’s likely any successful cure process will involve a combination of
approaches.

Promising results in some of the cure studies raise their own ethical
questions, as people who are doing well on successful HIV treatment would
have to stop to see if a functional cure has been achieved. An ethics
working group has been set up to address these issues.

Steven Deeks, co-chair with Francois Barré-Sinoussi of the IAS HIV Cure
working group, said: "The barriers to a cure are far greater than barriers
to antiretroviral therapy [in the late 1980s]… Unless we get very lucky
this is going to take well over a decade."

"The field is moving fast", said Sharon Lewin from Monash University in
Melbourne. "We certainly don’t have a cure currently, but we have a better
understanding of what we need to do."
  Related links

   - View full news story on aidsmap
   <http://www.aidsmap.com/page/2455081/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View abstract THAA0101 on the conference
website<http://pag.aids2012.org/Abstracts.aspx?SID=274&AID=6016>
   - View abstract THAA0103 on the conference
website<http://pag.aids2012.org/Abstracts.aspx?SID=274&AID=16010>

 One year’s preventive therapy reduces the risk of TB in people on HIV
treatment

Image: WHO/TBP/Gary Hampton

Twelve months of isoniazid (INH) preventive therapy (IPT) significantly
reduced the incidence of all TB diagnoses in people with HIV who are also
on antiretroviral therapy (ART), according to large randomised study
conducted in Khayelitsha, South Africa.

“There was a 37% reduction in the rate of incident TB in the INH treatment
group compared to those who were receiving ART alone,” said Dr Molebogeng
Xheedhe Rangaka of the University of Cape Town, who presented the study
findings.

This was a ‘late breaker’ at the conference and a full news story will be
published on aidsmap
tomorrow.<http://www.aidsmap.com/aids2012/News-from-AIDS-2012/page/2331052/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
  Related links

   - See aidsmap’s ‘News from AIDS 2012’ page for full story on Saturday
   28th July<http://www.aidsmap.com/aids2012/News-from-AIDS-2012/page/2331052/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>

 HIV and TB

In other TB news, infection with HIV does not have an impact on the time
taken to cure multidrug-resistant tuberculosis (MDR-TB), results of a study
conducted in Botswana
show<http://www.aidsmap.com/HIV-status-found-to-have-no-impact-on-multi-drug-resistant-TB-treatment-outcomes-in-Botswana/page/2454397/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.

TB<http://www.aidsmap.com/Tuberculosis/page/1044796/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>is
one of the most important causes of serious illness and death in
people
with HIV.

Strains of TB have emerged that are resistant to key
drugs<http://www.aidsmap.com/Drug-resistant-TB/page/1060305/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.
Treatment for MDR-TB is more complicated than therapy for drug-sensitive TB
and it also takes longer.

The results of the latest study show that therapy for MDR-TB has the same
success rate in HIV-positive people as in people who are HIV negative.

In addition, the duration of treatment needed to achieve a cure did not
differ by HIV status.
  Related links

   - View full news report on
aidsmap<http://www.aidsmap.com/HIV-status-found-to-have-no-impact-on-multi-drug-resistant-TB-treatment-outcomes-in-Botswana/page/2454397/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View the abstract on the conference
website<http://pag.aids2012.org/abstracts.aspx?aid=4278>
   - View the webcast of the presentation on the conference
website.<http://pag.aids2012.org/flash.aspx?pid=1417>

 Keeping people in HIV care

Images from the presentation of Dr Rachel Baggaley of the World Health
Organisation.

Community-based support increases the likelihood that HIV-positive people
will be retained in care, research conducted in South Africa
shows<http://www.aidsmap.com/Community-based-support-aids-retention-adherence-and-treatment-response/page/2453485/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

Less than a third of people who start HIV
therapy<http://www.aidsmap.com/Starting-HIV-treatment/page/1230814/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>in
southern Africa stay in HIV care. This is of serious concern. It means
that the majority of people with HIV are not receiving the health benefits
that come from specialist treatment and care. A high drop-out rate from
care also seriously undermines the use of HIV treatment as
prevention<http://www.aidsmap.com/HIV-treatment-as-prevention/page/2182221/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.

A speaker from the World Health Organization (WHO) presented findings from
research in more than 20 countries about why people fall out of care at
some point in the ‘cascade’ of HIV care (that is, the different stages of
care from first being tested to being on effective treatment ). Reasons
include the fear of
stigma<http://www.aidsmap.com/HIV-stigma-and-discrimination/page/1260701/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>,
denial about their condition, anxiety, poor links with the care available,
inadequate clinic facilities and problems with travel.

But a South African study showed that providing community-based
adherence<http://www.aidsmap.com/Adherence/page/1044469/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>support
increased the chances that people starting HIV treatment would stay
in care.

A new healthcare role of ‘patient advocates’ was introduced in 2004. These
workers help support adherence and also provide counselling and
psychosocial support.

Only 6% of people who had an advocate dropped out of care, compared to 10%
of individuals who did not receive this kind of support.

Separate research showed that contact tracing could help reduce drop-out
rates among children after starting HIV
treatment<http://www.aidsmap.com/Community-based-support-aids-retention-adherence-and-treatment-response/page/2453485/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

Following the introduction of active contact tracing, rates of
loss-to-follow-up were reduced from 22.7% to 8.5%.

The WHO report recommends the involvement of lay health workers to help
ensure people move from one stage of the care ‘cascade’ to the next, and
therefore stay in care.
In partnership with UNICEF <http://www.unicef.org>
  Related links

   - View full news report on
aidsmap<http://www.aidsmap.com/Community-based-support-aids-retention-adherence-and-treatment-response/page/2453485/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View information on the session, including links to the abstracts and
   slides from the presentations, on the conference
website<http://pag.aids2012.org/Session.aspx?s=234>

 Retaining children in HIV care

Rene Ekpini of UNICEF. © IAS/Steve Shapiro - Commercialimage.net

On the same theme of keeping people in care, the Washington conference was
told that three-quarters of children in need of HIV therapy are not
receiving treatment, an unacceptable
situation<http://www.aidsmap.com/page/2454665/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.

However, a variety of schemes show that this situation can be remedied.

One, implemented in
Malawi<http://www.aidsmap.com/Transforming-PMTCT-programmes-into-ART-programmes-UNICEF-champions-lifelong-treatment-for-all-HIV-positive-pregnant-women/page/2452760?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>,
includes the provision of lifelong HIV treatment to all HIV-positive
pregnant women, regardless of their CD4 cell count.

Another intervention in Zimbabwe has increased rates of diagnoses among
children.

A number of practical measures – often with the local community playing a
pivotal role – were also improving the retention of children in care.

These included:

   - Use of community volunteers to accompany children to clinic
   appointments.
   - Patient advocacy.
   - Provision of transport vouchers.

In partnership with UNICEF <http://www.unicef.org>
  Related links

   - View full news report on
aidsmap<http://www.aidsmap.com/page/2454665/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View information on the satellite session, with links to slides, on
   the conference website <http://pag.aids2012.org/session.aspx?s=21>
   - View abstract THAE0101 on the conference
website<http://pag.aids2012.org/abstracts.aspx?aid=12419>
   - View the slides from the presentation on the conference
website<http://pag.aids2012.org/PAGMaterial/aids2012/PPT/1228_2012/final.pptx>

 Access to treatment

Protester at the Say it loud! march in Washington. Image by Greta Hughson/
aidsmap.com

Patents and intellectual property rights are still restricting access to
antiretroviral therapy in middle- and low-income countries, the Washington
conference was told<http://www.aidsmap.com/Intellectual-property-still-a-threat-to-antiretroviral-access-says-panel/page/2453627/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

The roll-out of antiretroviral therapy in poorer countries has been made
possible in part due to the development of cheaper, generic formulations of
a number of key anti-HIV
drugs<http://www.aidsmap.com/resources/Antiretroviral-drugs-chart/page/1412453?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

However, the maintenance of intellectual property rights means that
medications needed for second- and third-line treatment remain
prohibitively expensive. The conference also heard of the especially high
cost of treatment for some middle-income countries.

Speakers at the session recommended that efforts were made to challenge
patent applications to ensure access to treatment takes priority.
  Related links

   - View full news story on
aidsmap<http://www.aidsmap.com/Intellectual-property-still-a-threat-to-antiretroviral-access-says-panel/page/2453627/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View information on the session, including links to the abstracts and
   slides from the presentations, on the conference
website<http://pag.aids2012.org/Session.aspx?s=228>

 HIV and the criminal law

Edwin J Bernard of the HIV Justice Network. © IAS/Ryan Rayburn -
Commercialimage.net

Draconian laws on HIV transmission and exposure were the focus of a session
at the International AIDS
Conference<http://www.aidsmap.com/In-the-real-world-HIV-has-changed-in-the-courtroom-it-is-still-the-1980s/page/2454299/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.

Delegates heard that courts often dismissed evidence regarding the
excellent prognosis<http://www.aidsmap.com/Prognosis/page/1044536/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>of
patients on HIV therapy and the impact
of HIV treatment on the risk of
transmission<http://www.aidsmap.com/HIV-treatment-as-prevention/page/2182221/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

People with HIV are being imprisoned after sexual encounters when they did
not disclose their status, even when no transmission occurred. In some
instances, people had been prosecuted even though the type of sex they had
engaged in involved no actual risk of HIV
transmission<http://www.aidsmap.com/How-transmission-occurs/cat/1613?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.

More encouragingly, the session was also told that lobbying could lead to
changes in the law.

For instance, Denmark suspended its tough HIV-specific laws after being
presented with scientific evidence about the life expectancy of people on
effective HIV therapy and the impact of treatment as
prevention<http://www.aidsmap.com/Infectiousness-and-treatment-as-prevention/cat/1624?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

  Related links

   - View full news report on
aidsmap<http://www.aidsmap.com/In-the-real-world-HIV-has-changed-in-the-courtroom-it-is-still-the-1980s/page/2454299?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View information on the session, including links to the abstracts,
   slides and webcasts from the presentations, on the conference
website<http://pag.aids2012.org/Session.aspx?s=232>

 HIV and hepatitis C

Vincent Lo Re of the University of Pennsylvania. Image ©Liz Highleyman /
hivandhepatitis.com

People co-infected with HIV and hepatitis C continue to have a higher risk
of serious liver disease than those who only have hepatitis
C<http://www.aidsmap.com/Decompensated-liver-disease-more-frequent-in-HIVHCV-co-infected-people/page/2453377/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

Researchers in the US compared rates of
liver<http://www.aidsmap.com/The-liver/page/1045123/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>disease
and liver-related death between
co-infected<http://www.aidsmap.com/Hepatitis-C/page/1045186/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>and
hepatitis C-monoinfected people.

Importantly, the co-infected participants were on HIV
treatment<http://www.aidsmap.com/HIV-treatment/page/1044497/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>,
which has previously been shown to slow the progression of liver
disease<http://www.aidsmap.com/Hepatitis-C/page/1506093/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

Co-infected people were at approximately twice the risk of developing
decompensated
liver disease<http://www.aidsmap.com/Hepatitis-C/page/1506093/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>and
69% more likely to progress to liver cancer.

An undetectable HIV viral
load<http://www.aidsmap.com/Viral-load/page/1044622/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>reduced
the risk of liver disease, but even with HIV suppression outcomes
were still poorer in co-infected people compared to those who only had
hepatitis C.
  Related links

   - View full news report on
aidsmap<http://www.aidsmap.com/Decompensated-liver-disease-more-frequent-in-HIVHCV-co-infected-people/page/2453377?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View the abstract on the conference
website<http://pag.aids2012.org/Abstracts.aspx?SID=213&AID=17867>
   - View the slides from the presentation on the conference
website<http://pag.aids2012.org/PAGMaterial/aids2012/PPT/1046_1343/lo%20re_ias_7-25-2012.final.pptx>

 Hormonal contraception and HIV risk

Contradictory evidence concerning the use of hormonal contraception and its
possible impact on the risk of infection with HIV was presented to the
International AIDS
Conference<http://www.aidsmap.com/page/2454435/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

Research published last
year<http://www.aidsmap.com/Hormonal-contraceptive-use-increases-womens-risk-of-acquiring-and-transmitting-HIV/page/1883604/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>showed
that women who used hormonal contraception had an increased risk of
infection with HIV and were also more likely to transmit the virus.

A re-analysis of the results of this study confirmed the association
between hormonal contraception and an increased risk of acquiring HIV.

The association between the use of hormonal
contraception<http://www.aidsmap.com/Contraceptive-choices-for-women-with-HIV/page/1439184/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>and
HIV risk remained significant when taking into account rates of
unprotected
sex<http://www.aidsmap.com/Unprotected-sex/page/1044912/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

However, a meta-analysis of studies looking at the risk of HIV and the use
of hormonal and non-hormonal forms of contraception failed to find any
definitive evidence that hormonal contraception increased the chances of
infection with HIV.

The point was made that access to reliable contraception is important for
women, and that any possible HIV risk has to be balanced with the
availability of effective contraception.
  Related links

   - View full news report on
aidsmap<http://www.aidsmap.com/page/2454435/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
   - View a complete listing of the session presentations, with links to
   abstracts and slides, on the conference
website<http://pag.aids2012.org/session.aspx?s=287>

 The global village

Images by Greta Hughson/aidsmap.com

The 19th International AIDS Conference (AIDS
2012)<http://www.aidsmap.com/aids2012?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>is
not just the sum of its presentations and posters. Alongside the
conference sessions, the exhibition halls and the global village have also
been a hive of activity this week.

Join *aidsmap*’s Greta Hughson on a tour of the global
village<http://www.aidsmap.com/page/2454743?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.
  Related links

   - The Global
Village<http://www.aidsmap.com/The-Global-Village/page/2454743/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>

 Support our work

As a charity we rely on donations to continue our work and are so grateful
for every gift we receive, no matter how big or small. Every single penny
is put towards helping people with HIV, and those who support and care for
them, access the vital information they need.

We believe passionately that independent, clear and evidence-based
information lies at the heart of empowering people to make decisions about
their health and live longer, healthier, happier lives.

Read about how your support makes a
difference<http://www.aidsmap.com/aboutus/How-your-support-makes-a-difference/page/1439296/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>and
if you can feel you can support our work with a donation, you can do
so
online at www.aidsmap.com/donate<http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
.

Thank you.

*“I was diagnosed with HIV in early December at the age of 24... I
initially couldn't bring myself to talk to even my closest friends or
family about the diagnosis and aidsmap.com has helped me beyond belief and
helped me to be able to talk to others in person.”*
  Related links

   - www.aidsmap.com/donate<http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>

       Two other official partners are providing coverage and analysis
online, so you can have the fullest picture of the conference. Clinical
Care Options (CCO)<http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202012.aspx>,
will be providing audio highlights, capsule summaries and downloadable
slidesets, while the Kaiser Family
Foundation<http://globalhealth.kff.org/aids2012>are providing
webcasting from conference sessions.

Connect with NAM on
Facebook<http://www.facebook.com/pages/NAM-the-HIVAIDS-information-charity/99971718192>:
Keep up to date with all the exciting projects, latest achievements and new
developments that are going on in the world of NAM.

Follow NAM on twitter for links to hot off the press news stories from our
editors covering key developments and conferences as they happen. Our news
feed is linked to www.twitter.com/aidsmap_news and we also tweet from
www.twitter.com/aidsmap.

Follow all the conference news by subscribing to our RSS
feeds<http://www.aidsmap.com/news/News-feeds/page/1444172/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>.

       AIDS 2012 conference coverage in partnership with:
<http://www.aids2012.org>
<http://www.unicef.org>

NAM is partnering with UNICEF to deliver the AIDS 2012 bulletins, which
have also been made possible thanks to support from Bristol-Myers Squibb
and Vestergaard Frandsen. NAM’s wider conference news reporting services
have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and
ViiV Healthcare.

NAM is an award-winning, community-based organisation, which works from the
UK. We deliver reliable and accurate HIV information across the world to
HIV-positive people and to the professionals who treat, support and care
for them.

Make a donation, make a difference at
www.aidsmap.com/donate<http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>

*For more details, please contact NAM:*
tel: +44 (0)20 3242 0820
fax: +44 (0)20 3242 0839
email: info at nam.org.uk
web: www.aidsmap.com<http://www.aidsmap.com/?utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>

*NAM Publications*
Registered office: 77a Tradescant Road, London, SW8 1XJ
Company limited by guarantee. Registered in England & Wales, number: 2707596
Registered charity, number: 1011220

To unsubscribe please visit:
http://www.aidsmap.com/page/1492854/<http://www.aidsmap.com/page/1492854/?type=x&utm_source=NAM-Email-Promotion&utm_medium=conference-bulletin&utm_campaign=English>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20120727/868fd910/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: English_Friday_27th_July_2012.pdf
Type: application/octet-stream
Size: 376718 bytes
Desc: not available
URL: <http://lists.resist.ca/pipermail/viva/attachments/20120727/868fd910/attachment-0001.obj>